Association of age and overall survival in capecitabine-treated patients with metastatic breast cancer in clinical trials

Joanne L. Blum, Joseph Kohles, Edward McKenna, Nana Scotto, Sylvia Hu, Dawn Odom, James A. Kaye, Stefan Glück

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

We sought to determine if an association exists between age and capecitabine efficacy among patients with metastatic breast cancer (MBC). Pooled analysis of five phase II or III registration trials of capecitabine 2,500-2,510 mg/m2/day for 2 weeks and 1 week off, or combination therapy was performed. Four trials enrolled patients previously exposed to other chemotherapy, generally a taxane. Of 570 patients, 193 (34%) were 18-49 years old, 246 (43%) were 50-64, and 131 (23%) were ≥65. Median average daily dose was 2,067 mg/m2 in the 18- to 49-year-old group and 2,105 mg/m 2 in the 50-64 and ≥65 year groups. Overall survival (OS) in all groups was similar by log-rank test for the individual trials (P = 0.71-0.95) and Cox regression of the pooled trials. Univariate analysis demonstrated no difference in clinical benefit or objective response between groups. Treatment failure analysis showed 283 (50%) patients experienced progressive disease, while 114 (20%) withdrew for safety. Serious adverse events (AEs) occurred in 71 (36.8%), 85 (34.6%), and 59 (45.0%) patients in the 18-49, 50-64, and ≥65 years groups, respectively. There was no statistically significant association between age and OS, clinical benefit, or objective response in patients with MBC treated with capecitabine. Frequency of AEs and serious AEs was not related to age at treatment, although women ≥65 years were more likely to withdraw from treatment because of an AE than younger women.

Original languageEnglish
Pages (from-to)431-439
Number of pages9
JournalBreast Cancer Research and Treatment
Volume125
Issue number2
DOIs
StatePublished - Jan 1 2011
Externally publishedYes

Fingerprint

Clinical Trials
Breast Neoplasms
Survival
Treatment Failure
Capecitabine
Therapeutics
Safety
Drug Therapy

Keywords

  • Age
  • Capecitabine
  • Chemotherapy
  • Clinical trial
  • Metastatic breast cancer
  • Tolerability

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Association of age and overall survival in capecitabine-treated patients with metastatic breast cancer in clinical trials. / Blum, Joanne L.; Kohles, Joseph; McKenna, Edward; Scotto, Nana; Hu, Sylvia; Odom, Dawn; Kaye, James A.; Glück, Stefan.

In: Breast Cancer Research and Treatment, Vol. 125, No. 2, 01.01.2011, p. 431-439.

Research output: Contribution to journalArticle

Blum, Joanne L. ; Kohles, Joseph ; McKenna, Edward ; Scotto, Nana ; Hu, Sylvia ; Odom, Dawn ; Kaye, James A. ; Glück, Stefan. / Association of age and overall survival in capecitabine-treated patients with metastatic breast cancer in clinical trials. In: Breast Cancer Research and Treatment. 2011 ; Vol. 125, No. 2. pp. 431-439.
@article{9bbe205654024adba35ffdf512925759,
title = "Association of age and overall survival in capecitabine-treated patients with metastatic breast cancer in clinical trials",
abstract = "We sought to determine if an association exists between age and capecitabine efficacy among patients with metastatic breast cancer (MBC). Pooled analysis of five phase II or III registration trials of capecitabine 2,500-2,510 mg/m2/day for 2 weeks and 1 week off, or combination therapy was performed. Four trials enrolled patients previously exposed to other chemotherapy, generally a taxane. Of 570 patients, 193 (34{\%}) were 18-49 years old, 246 (43{\%}) were 50-64, and 131 (23{\%}) were ≥65. Median average daily dose was 2,067 mg/m2 in the 18- to 49-year-old group and 2,105 mg/m 2 in the 50-64 and ≥65 year groups. Overall survival (OS) in all groups was similar by log-rank test for the individual trials (P = 0.71-0.95) and Cox regression of the pooled trials. Univariate analysis demonstrated no difference in clinical benefit or objective response between groups. Treatment failure analysis showed 283 (50{\%}) patients experienced progressive disease, while 114 (20{\%}) withdrew for safety. Serious adverse events (AEs) occurred in 71 (36.8{\%}), 85 (34.6{\%}), and 59 (45.0{\%}) patients in the 18-49, 50-64, and ≥65 years groups, respectively. There was no statistically significant association between age and OS, clinical benefit, or objective response in patients with MBC treated with capecitabine. Frequency of AEs and serious AEs was not related to age at treatment, although women ≥65 years were more likely to withdraw from treatment because of an AE than younger women.",
keywords = "Age, Capecitabine, Chemotherapy, Clinical trial, Metastatic breast cancer, Tolerability",
author = "Blum, {Joanne L.} and Joseph Kohles and Edward McKenna and Nana Scotto and Sylvia Hu and Dawn Odom and Kaye, {James A.} and Stefan Gl{\"u}ck",
year = "2011",
month = "1",
day = "1",
doi = "10.1007/s10549-010-1222-3",
language = "English",
volume = "125",
pages = "431--439",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Association of age and overall survival in capecitabine-treated patients with metastatic breast cancer in clinical trials

AU - Blum, Joanne L.

AU - Kohles, Joseph

AU - McKenna, Edward

AU - Scotto, Nana

AU - Hu, Sylvia

AU - Odom, Dawn

AU - Kaye, James A.

AU - Glück, Stefan

PY - 2011/1/1

Y1 - 2011/1/1

N2 - We sought to determine if an association exists between age and capecitabine efficacy among patients with metastatic breast cancer (MBC). Pooled analysis of five phase II or III registration trials of capecitabine 2,500-2,510 mg/m2/day for 2 weeks and 1 week off, or combination therapy was performed. Four trials enrolled patients previously exposed to other chemotherapy, generally a taxane. Of 570 patients, 193 (34%) were 18-49 years old, 246 (43%) were 50-64, and 131 (23%) were ≥65. Median average daily dose was 2,067 mg/m2 in the 18- to 49-year-old group and 2,105 mg/m 2 in the 50-64 and ≥65 year groups. Overall survival (OS) in all groups was similar by log-rank test for the individual trials (P = 0.71-0.95) and Cox regression of the pooled trials. Univariate analysis demonstrated no difference in clinical benefit or objective response between groups. Treatment failure analysis showed 283 (50%) patients experienced progressive disease, while 114 (20%) withdrew for safety. Serious adverse events (AEs) occurred in 71 (36.8%), 85 (34.6%), and 59 (45.0%) patients in the 18-49, 50-64, and ≥65 years groups, respectively. There was no statistically significant association between age and OS, clinical benefit, or objective response in patients with MBC treated with capecitabine. Frequency of AEs and serious AEs was not related to age at treatment, although women ≥65 years were more likely to withdraw from treatment because of an AE than younger women.

AB - We sought to determine if an association exists between age and capecitabine efficacy among patients with metastatic breast cancer (MBC). Pooled analysis of five phase II or III registration trials of capecitabine 2,500-2,510 mg/m2/day for 2 weeks and 1 week off, or combination therapy was performed. Four trials enrolled patients previously exposed to other chemotherapy, generally a taxane. Of 570 patients, 193 (34%) were 18-49 years old, 246 (43%) were 50-64, and 131 (23%) were ≥65. Median average daily dose was 2,067 mg/m2 in the 18- to 49-year-old group and 2,105 mg/m 2 in the 50-64 and ≥65 year groups. Overall survival (OS) in all groups was similar by log-rank test for the individual trials (P = 0.71-0.95) and Cox regression of the pooled trials. Univariate analysis demonstrated no difference in clinical benefit or objective response between groups. Treatment failure analysis showed 283 (50%) patients experienced progressive disease, while 114 (20%) withdrew for safety. Serious adverse events (AEs) occurred in 71 (36.8%), 85 (34.6%), and 59 (45.0%) patients in the 18-49, 50-64, and ≥65 years groups, respectively. There was no statistically significant association between age and OS, clinical benefit, or objective response in patients with MBC treated with capecitabine. Frequency of AEs and serious AEs was not related to age at treatment, although women ≥65 years were more likely to withdraw from treatment because of an AE than younger women.

KW - Age

KW - Capecitabine

KW - Chemotherapy

KW - Clinical trial

KW - Metastatic breast cancer

KW - Tolerability

UR - http://www.scopus.com/inward/record.url?scp=78650989470&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650989470&partnerID=8YFLogxK

U2 - 10.1007/s10549-010-1222-3

DO - 10.1007/s10549-010-1222-3

M3 - Article

VL - 125

SP - 431

EP - 439

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -